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Putting genomics into practice
A new analysis casts doubt on the clinical utility of CYP2C19 genotype testing to help guide
antiplatelet prescribing
Michael V Holmes Medical Research Council population health scientist fellow 1, Juan P Casas
senior lecturer in epidemiology 2, Aroon D Hingorani professor of genetic epidemiology 1
1Genetic Epidemiology Research Group, Department of Epidemiology and Public Health, University College London, London WC1E 6BT, UK;
2Faculty of Epidemiology and Public Health, London School of Hygiene and Tropical Medicine, London, UK
Variation in the human genome has long been considered to
contribute to individual differences in disease susceptibility and
drug response. But a key question for clinical practice is whether
knowledge of a patient’s genotype could be useful for stratifying
disease risk or guiding treatment. In the linked systematic review
(doi:10.1136/bmj.d4588) Bauer and colleagues report a
systematic review and meta-analysis of studies examining the
association of variation in the CYP2C19 gene and
atherothrombotic events during treatment with clopidogrel.1
The sequence of the human genome is now known,2 as are the
positions of the several million nucleotides that differ most
commonly from one person to the next and their inheritance
patterns in different human populations. Laboratory and
analytical techniques now permit rapid cost effective direct (and
indirect) genotyping of many single nucleotide polymorphisms
(SNPs) in the genomes of many thousands of people to gain
insight into the regions that influence disease related biomarkers,
susceptibility to common diseases, or the response to widely
prescribed drugs.
By 2011, nearly 1000 such genome-wide association studies
had reported their findings (figure).3 Genome-wide association
studies of disease risk are typically large and collaborative, and
the results have usually been replicated in independent samples
before publication. This means that the findings are not only
among the most novel but also the most secure in any field of
biomedicine. Although the precise causal genetic variants have
yet to be defined with certainty in most cases, these studies have
already provided early insights into disease pathogenesis that
will probably yield future dividends in the form of new
treatments.4
Cumulative number of genome-wide association studies
curated by the National HumanGenomeResearch Institute
(www.genome.gov/gwastudies )
Unfortunately, information on common SNPs is proving less
helpful for predicting disease risk than had been hoped 5: the
common genetic variants that have been studied so far have too
weak an effect. A panel of disease-associated SNPs may be
more helpful for estimating risk at a group level, but only a
minority of people in any population possess genomes with a
large number of common risk variants. They are outnumbered
by those with an intermediate number of common risk variants,
who account for more of the cases, so even panels of SNPs
associated with common diseases tend to perform poorly in
distinguishing between those who will and will not become
affected by a common disease.6 Rare genetic variants that are
now being sought by high throughput DNA sequencing are
predicted to have a larger effect on disease risk than common
alleles.7 However, by their nature, few people in the population
would harbour such variants, which reduces their usefulness for
population-wide screening. Nevertheless, there is hope that rare,
a.hingorani@ucl.ac.uk
Table supplied by the author (see http://www.bmj.com/content/343/bmj.d4953/suppl/DC1)
Reprints: http://journals.bmj.com/cgi/reprintform Subscribe: http://resources.bmj.com/bmj/subscribers/how-to-subscribe
BMJ 2011;343:d4953 doi: 10.1136/bmj.d4953 Page 1 of 2
Editorials
EDITORIALS
highly penetrant disease associated variants might provide an
effective means of family based screening for certain disorders.
The area of personalised (or stratified) medicine, which is
currently attracting substantial interest from industry, funders,
and scientists, represents another potential application of the
emerging genomic advances. Already, several established cancer
treatments target cellular alterations caused by mutations or
rearrangements in the genome of cancer cells.8 9 But, could
inherited differences in drug response
(pharmacogenetics)—mediated through alterations in the level
or activity of proteins involved in absorption, metabolism, and
elimination of drugs (pharmacokinetic-pharmacogenetics)—or
the protein targets of drug action
(pharmacodynamic-pharmacogenetics), help to predict treatment
benefits and harms?
A few high profile examples illustrate the potential of
pharmacogenetics (table; see bmj.com), but recommendations
on the use of pharmacogenetic tests in clinical practice are often
inconsistent. Moreover, a recent overview (covering
pharmacogenetic studies between 1967 and 2008) highlighted
several problems in this field.10 These include a preponderance
of reviews over primary research articles, under-representation
of certain disease areas and ethnic groups, small sample sizes,
a relative dearth of genome-wide association studies (figure);
widespread use of surrogate outcome measures; and evidence
of small study bias, of which publication bias is one cause. Poor
study quality could delay the clinical development of valuable
pharmacogenetic tests but also lead to premature adoption of
poorly validated tests.
In their systematic review and meta-analysis, Bauer and
colleagues evaluated the strength of evidence on the association
between the variation in the CYP2C19 gene and
atherothrombotic events during treatment with clopidogrel.1
Clopidogrel, a widely prescribed, now off-patent, antiplatelet
agent (originally licensed as Plavix), requires metabolism for
its activation. Several hepatic cytochrome enzymes contribute
to this, including CYP2C19. There is an emerging view that
people who carry reduced activity CYP2C19 gene variants are
less well protected from cardiovascular events during
clopidogrel treatment and that genotype based tests could help
inform decisions on the dose of clopidogrel, or whether to opt
for newer more expensive (patented) antiplatelet drugs such as
prasugrel or ticagrelor, which are considered less dependent on
metabolism for their activation.
After several research articles on the association between
CYP2C19 genotype and response to clopidogrel, the US Food
andDrugAdministration (FDA) issued a boxedwarning,11which
notified clinicians “about reduced effectiveness in patients who
are poor metabolizers of Plavix” and “that tests are available to
identify genetic differences in CYP2C19 function;” it also
advised them “to consider use of other anti-platelet medications
or alternative dosing strategies for Plavix in patients identified
as poor metabolizers.”
The analysis by Bauer and colleagues has now unearthed
evidence of small study bias in the literature relating to this area,
with weakening of the overall association when more recent
larger studies are added. The authors also identified
inconsistencies between studies in relation to genotyping, study
outcomes, and effect estimates that collectively question the
validity ofCYP2C19 genotype testing to help guide antiplatelet
treatment decisions.
The problems identified by Bauer and colleagues may not be
unique to CYP2C19 genotyping and clopidogrel response.12
Efforts to strengthen the design, analysis, reporting, and
appraisal of pharmacogenetic studies, drawing on experience
from observational studies, gene-disease association studies,
cancer biomarker studies, genetic tests as predictors of disease
risk, and randomised trials, may now be needed to enable more
efficient clinical translation of the emerging genomic
discoveries.
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